Patents Assigned to Biogen Idec
  • PLATELET AGGREGATION ASSAYS
    Publication number: 20130189713
    Abstract: The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto.
    Type: Application
    Filed: February 25, 2013
    Publication date: July 25, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventor: BIOGEN IDEC MA INC.
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
    Publication number: 20130183289
    Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.
    Type: Application
    Filed: September 13, 2008
    Publication date: July 18, 2013
    Applicant: Biogen Idec MA Inc
    Inventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
  • NON-FUCOSYLATED ANTIBODIES
    Publication number: 20130183288
    Abstract: The present invention provides non-fucosylated therapeutic antibodies. More particularly, the invention provides non-fucosylated anti-CD20, anti-CD23 and anti-CD80 antibodies, which show enhanced antibody effector functions. Also provided are cells expressing the non-fucosylated antibodies and therapeutic methods using the non-fucosylated antibodies.
    Type: Application
    Filed: March 28, 2008
    Publication date: July 18, 2013
    Applicant: BIOGEN IDEC INC.
    Inventors: Mitchell Reff, Kandasamy Hariharan, MacLaren Ann, Sisk William
  • Treatment of conditions involving demyelination
    Patent number: 8486893
    Abstract: The invention provides methods of treating diseases, disorsers or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: July 16, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, John McCoy
  • Method of Treating Immunological Disorders by Administering Truncated BAFF Receptors
    Publication number: 20130177558
    Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.
    Type: Application
    Filed: October 4, 2012
    Publication date: July 11, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventor: Biogen Idec MA Inc.
  • Factor IX Polypeptides and Methods of Use Thereof
    Publication number: 20130171175
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: March 11, 2013
    Publication date: July 4, 2013
    Applicant: BIOGEN IDEC HEMOPHILIA INC.
    Inventor: BIOGEN IDEC HEMOPHILIA INC.
  • Detection and quantitation of cyclodextrins
    Patent number: 8465935
    Abstract: The invention relates to the detection and quantitation of cyclodextrins and cyclodextrin derivatives in solutions comprising a protein. The invention further relates to methods of evaluating pharmaceutical preparations for the presence of residual cyclodextrins.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: June 18, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Zoran Sosic, Rulin Qian, James Ahern, Rohin Mhatre
  • Methods for inhibiting lymphotoxin-? receptor signaling in TH1 cell-associated disorders
    Patent number: 8455445
    Abstract: This invention relates to compositions and methods comprising “lymphotoxin-?-receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-? receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-? receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: June 4, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
  • TREATMENT USING NEUBLASTIN POLYPEPTIDES
    Publication number: 20130130981
    Abstract: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.
    Type: Application
    Filed: September 4, 2012
    Publication date: May 23, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventor: Dinah W. Y. Sah
  • Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
    Patent number: 8440189
    Abstract: The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: May 14, 2013
    Assignee: Biogen Idec MA Inc.
    Inventor: Paul Rennert
  • NOVEL NEUROTROPHIC FACTORS
    Publication number: 20130109624
    Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
    Type: Application
    Filed: June 27, 2012
    Publication date: May 2, 2013
    Applicants: NSGENE A/S, BIOGEN IDEC MA INC.
    Inventors: Dinah W.Y. Sah, Teit E. Johansen, Anthony Rossomando
  • Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
    Publication number: 20130108629
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: December 6, 2010
    Publication date: May 2, 2013
    Applicant: BIOGEN IDEC HEMOPHILIA INC.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • Methods of treating lupus nephritis using antibodies against monocyte chemotactic proteins
    Patent number: 8431125
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: April 30, 2013
    Assignee: Biogen Idec MA, Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • LIGHT TARGETING MOLECULES AND USES THEREOF
    Publication number: 20130101549
    Abstract: LIGHT-targeting molecules (e.g., LIGHT fusion molecules), compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.
    Type: Application
    Filed: October 25, 2012
    Publication date: April 25, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventor: BIOGEN IDEC MA INC.
  • METHODS FOR THE DETECTION OF JC POLYOMA VIRUS
    Publication number: 20130101985
    Abstract: Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.
    Type: Application
    Filed: February 5, 2010
    Publication date: April 25, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Leonid Gorelik, Alexey Lugovskoy
  • Composition comprising antibodies to LINGO or fragments thereof
    Patent number: 8425910
    Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: April 23, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Christilyn Graff
  • Method of Supplementing Culture Media to Prevent Undesirable Amino Acid Substitutions
    Publication number: 20130096283
    Abstract: The present invention relates to methods of reducing substitution of amino acids during the production of polypeptides of interest in mammalian cells. By varying the concentration of amino acids in the culture medium, heterogeneity of the polypeptide's amino acid sequence is decreased, leading to higher yields of functional protein.
    Type: Application
    Filed: November 24, 2009
    Publication date: April 18, 2013
    Applicant: Biogen Idec MA inc.
    Inventors: Anurag Khetan, Yao-ming Huang, Jana Dolnikova, Nels Pederson, Helena Yusuf-Makagiansar, Paul Chen, Thomas Ryll
  • TREATING NEUROLOGICAL DISORDERS
    Publication number: 20130095175
    Abstract: Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or a TWEAK receptor blocking agents are presented.
    Type: Application
    Filed: December 18, 2012
    Publication date: April 18, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventor: Biogen Idec Ma Inc.
  • NEUBLASTIN VARIANTS
    Publication number: 20130096065
    Abstract: Variant Neublastin polypeptides having substitutions at selected amino acid residues are disclosed. Substitution at one or more selected amino acid residues decreases heparin binding and increases serum exposure of variant Neublastin polypeptides. Also disclosed are methods of using variant Neublastin polypeptides to treat disorders and activate the RET receptor in a mammal.
    Type: Application
    Filed: July 3, 2012
    Publication date: April 18, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Anthony Rossomando, Laura Silvian, R. Blake Pepinsky
  • KIM-1 ANTIBODIES FOR TREATMENT OF TH2-MEDIATED CONDITIONS
    Publication number: 20130089539
    Abstract: Compositions and methods for treating Th2- and Th1-mediated disease are provided.
    Type: Application
    Filed: April 4, 2012
    Publication date: April 11, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Paul Rennert, Patricia McCoon, Veronique Bailly, Alexey Lugovskoy